News

All of Ferrer’s information, just a click away

normal

The World Health Organization includes the cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines

.

Tue, 08/01/2023 - 10:58

We allocate, on average, more than 40% of our profits to social and environmental projects for the third consecutive year

.

Wed, 07/26/2023 - 10:13

Ferrer4Future launches its open innovation challenge to drive digital solutions for ALS

.

Fri, 06/23/2023 - 07:24

We extend our clinical study in amyotrophic lateral sclerosis (ALS)

.

Thu, 06/22/2023 - 06:30

We’ve been awarded EcoVadis GOLD Rating!

.

Thu, 03/30/2023 - 09:29

Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP)

.

Wed, 02/22/2023 - 09:30

We achieve Great Place To Work certification in 5 countries

.

Tue, 11/29/2022 - 18:17

More than 500 people from Ferrer participate in positive impact activities in nine countries on the Days for Good

.

Fri, 10/07/2022 - 10:02

The polypill reduces cardiovascular mortality by 33% in patients treated after myocardial infarction

.

Thu, 08/25/2022 - 11:55

We invested more than 60% of our net profits in social and environmental causes

.

Thu, 07/28/2022 - 13:56

For requests for interviews or information, please contact the Communications Department

alternatively, please dial +34 936 003 779

See more

Business Development